BioCryst Pharmaceuticals (MEX:BCRX) Tax Provision: MXN-69 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BCRX BioCryst Pharmaceuticals Inc MEX:BCRX
55 GF Score
Price MXN182.00
GF Value MXN217.47
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Tax Provision?

BioCryst Pharmaceuticals MEX:BCRX 55 Tax Provision is MXN-69 Mil as of Mar. 2026. GuruFocus rates MEX:BCRX with a GF Score™ of 55/100 and a GF Value™ of MXN217.47 (Modestly Undervalued). The stock has 3 warning signs investors should review.

BioCryst Pharmaceuticals's tax provision for the three months ended in Mar. 2026 was MXN-18 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-69 Mil.

BioCryst Pharmaceuticals Tax Provision Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Tax Provision Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.22 -53.28 -5.26 -40.19 -63.56

BioCryst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.85 -26.38 14.11 -39.11 -18.11
MEX:BCRX
55GF Score
BioCryst Pharmaceuticals Inc MEX:BCRX
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of MXN-69 Mil mean?
BioCryst Pharmaceuticals (MEX:BCRX) has a Tax Provision of MXN-69 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on BioCryst Pharmaceuticals and its competitors.
Is BioCryst Pharmaceuticals' Tax Provision too high?
BioCryst Pharmaceuticals' current Tax Provision is MXN-69 Mil. Overall, BioCryst Pharmaceuticals has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Tax Provision compare to SUPN and PBH?
BioCryst Pharmaceuticals' Tax Provision of MXN-69 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Drug Manufacturers company?
A good Tax Provision depends on the Drug Manufacturers industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on BioCryst Pharmaceuticals and its competitors. BioCryst Pharmaceuticals's current Tax Provision is MXN-69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (MEX:BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN217.47, compared to a current price of MXN182.00 — trading 16.3% below its estimated fair value. The current Tax Provision is MXN-69 Mil. BioCryst Pharmaceuticals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For BioCryst Pharmaceuticals (MEX:BCRX), the current Tax Provision is MXN-69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (MEX:BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of MXN182.00 is trading 16.3% below its estimated GF Value™ of MXN217.47. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:BCRX:

  • Tax Provision: MXN-69 Mil
  • GF Value™: MXN217.47 vs. price of MXN182.00 (16.3% below fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the MEX:BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:USABO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
55GF Score

Get the complete analysis for MEX:BCRX

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN182.00
Price
MXN217.47
GF Value